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Introduction
Phaeochromocytomas are catecholamine-secreting tumours that 
arise from chromaffin tissue. The majority of tumours arise within the 
adrenal gland and are benign; extra-adrenal phaeochromocytomas 
are also referred to as paragangliomas. Approximately 76% of 
phaeochromocytomas occur sporadically; the remaining 24% 
are familial, and therefore genetic conditions, including multiple 
endocrine neoplasia type 2 (MEN2), neurofibromatosis type 1 
(NF1), Von Hippel-Lindau (VHL) syndrome and hereditary paraganglioma-
phaeochromocytoma syndrome should be considered as part of the 
differential diagnosis.1 In this article, we report on two black families 
with unusual phaeochromocytomas, diagnosed with VHL syndrome.
CASE 1
A 26-year-old black South African man was admitted to the Chris Hani 
Baragwanath Hospital in August 2008. His presentation was dominated 
by neurological abnormalities: vertigo, unsteadiness of gait, loss of 
balance, and chronic headache. He complained of weight loss and 
occasional palpitations. Examination revealed a thin patient with a 
marfanoid habitus (height 1.90 m; arm span 2.06 m) (arm span:height 
ratio = 1.08; normal < 1.05), a marginally elevated blood pressure (BP 
150/100 mmHg), horizontal nystagmus and an inability to stand up.  
A magnetic resonance imaging scan (MRI) of the brain and spinal cord 
showed a haemangioblastoma (Figure 1, arrow) and an associated 
large cyst in the cerebellar vermis with obstructive hydrocephalus. 
The spinal cord was normal. Given the rarity of central nervous 
system haemangioblastomas, and their known association with 
phaeochromocytomas in VHL syndrome, urinary metanephrine 
levels were requested and were found to be markedly elevated. 
Abdominal computed tomography scan (CT) and iodine-131-meta-
iodobenzylguanidine (MIBG) scanning confirmed the presence of a right 
adrenal phaeochromocytoma. The kidneys were normal.
The presence of both a cerebellar haemangioblastoma and adrenal 
phaeochromocytoma fulfilled diagnostic criteria for VHL syndrome.2
The patient had his phaeochromocytoma and cerebellar haeman-
gioblastoma successfully removed, with complete recovery.
Genetic counselling was provided for the family in association with 
the Clinical Section of the Division of Human Genetics, National Health 
Laboratory Service. Confirmatory genetic testing was performed and a 
missense mutation (c. 256C > T) in the VHL gene on chromosome 3p 
was identified on sequence analysis. Following the characterisation of 
the genetic mutation in the proband, predictive testing was offered to 
at-risk family members (Figure 2).              
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Figure 1: MRI brain and spinal cord index patient, Case 1
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CASE 2
A 29-year-old, previously healthy black woman, originally from the 
Democratic Republic of Congo, attended routine antenatal care at the 
Rahima Moosa Mother and Child Hospital in Johannesburg for her third 
pregnancy in August 2009. Antenatal ultrasound dated the pregnancy 
at 20 weeks’ gestation. At this time, she was diagnosed with severe 
hypertension and an ultrasound examination revealed a unilateral 
adrenal mass, measuring 4.8 cm x 5.4 cm x 5.9 cm. A diagnosis 
of phaeochromocytoma was considered when 24-hour urinary 
metanephrine assessment showed markedly elevated levels.
MRI scanning at the Charlotte Maxeke Johannesburg Academic 
Hospital confirmed the presence of bilateral adrenal tumours (Figure 
3). Subsequent preoperative management involved a multi-disciplinary 
team. A laparotomy was undertaken to remove both tumours. A few days 
after the successful removal of the tumours, she had a miscarriage. 
Although substantial improvement in her blood pressure was noted after 
the surgery, she remains on antihypertensive therapy.
Histological evaluation of the tumour tissue confirmed features 
consistent with a phaeochromocytoma, with no evidence of capsular or 
vascular invasion.
The rare presentation of bilateral phaeochromocytomas in a young 
patient raised the suspicion of a genetic tumour syndrome even 
though her family history was negative. Genetic testing for VHL 
syndrome was conducted, as part of the genetic work-up for bilateral 
phaeochromocytomas. Testing was positive for a missense mutation (c. 
499C > T) in the VHL gene.
In view of her diagnosis, additional investigations, including MRI brain 
and spinal cord, CT abdomen and ophthalmological assessment, were 
performed. A haemangioblastoma was detected at the C3 level of the 
spinal cord, extending to C6; other investigations were normal. After 
genetic counselling, predictive genetic testing for her two children was 
performed and the results are pending. If found to be positive, early 
screening measures to detect VHL-associated tumours will be instituted. 
Discussion
As at least 24% of phaeochromocytomas may be genetic in origin,1 a 
high index of suspicion must exist in deciding which patients would 
benefit from genetic testing. Rare tumours, multiple primary tumours, 
neoplasia detected at a younger age than expected for the specific 
tumour, unusual tumour sites and a strong family history of tumours are 
suggestive of a genetic aetiology. 
In the case of bilateral phaeochromocytoma or phaeochromocytoma 
associated with other tumours, the following autosomal dominant 
genetic conditions should be considered, with genetic counselling and 
testing being offered:
1. VHL is characterised by retinal angiomas; central nervous system 
haemangioblastomas; clear-cell renal cell carcinomas; pancreatic 







Figure 2: Family pedigree, Case 1
I 1: Index patient’s father:
• Posterior fossa brain tumour – removed 1994
• Bilateral renal cell carcinoma – right nephrectomy and radiofrequency ablation 
of left kidney in 2008
II 2: Index patient:
• Cerebellar haemangioblastoma and adrenal phaeochromocytoma
II 3: Index patient’s sister:
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and epididymal cysts; and phaeochromocytomas. Mutations in the 
VHL gene are highly penetrant and most people carrying a mutation 
will develop symptoms by the age of 65.2 
2. Multiple endocrine neoplasia type 2 (MEN2A) is characterised 
by medullary thyroid carcinomas (in 96% of affected individuals), 
phaeochromocytomas (in 50% of affected individuals) and 
parathyroid hyperplasia (in 20 to 30% of affected individuals). 
MEN2A is caused by mutations in the RET proto-oncogene. Most 
affected individuals require annual biochemical screening for 
phaeochromocytomas and parathyroid hyperplasia.3
3. Hereditary paraganglioma-phaeochromocytoma syndrome is 
characterised by paragangliomas, mostly of the head and neck, and 
phaeochromocytomas. The genes responsible for this syndrome 
are the succinate dehydrogenase subunit genes: SDHB, SDHD and 
SDHC.4
4. Neurofibromatosis type 1 (NF1) is characterised by café au lait 
spots, cutaneous neurofibromas, plexiform neurofibromas, Lisch 
nodules and axillary and inguinal freckling. Phaeochromocytomas, 
although described in NF1, are rare and usually unilateral. NF1 is 
caused by mutations in the NF1 gene.4
Molecular testing for VHL and MEN2A is available in South Africa, while 
SDHC, SDHD and SDHB testing can be arranged overseas through the 
Division of Human Genetics at the National Health Laboratory Service. 
Genetic testing for NF1 is not offered in South Africa; however, the 
clinical diagnostic criteria are thought to be both sensitive and specific.
In autosomal dominant conditions, siblings and offspring of affected 
individuals have up to a 50% risk of inheriting the mutation and 
developing early neoplasia. The importance of recognising and 
diagnosing genetic conditions allows not only for the improved 
surveillance and management of the affected individual, but also for 
assessing and managing at-risk family members. Genetic testing of 
at-risk family members can markedly alter the risk profile of these 
individuals, sparing time and exorbitant funds if they test negative and 
improving surveillance, early detection and possibly outcome if they test 
positive for the mutation.
Conclusion
These two cases illustrate black families with VHL syndrome and 
highlight the value of genetic counselling and testing in the setting 
of unusual phaeochromocytomas. Genetic testing should always be 
considered for the affected individual in cases of young onset and 
multiple or rare tumours, even if the family history is not suggestive of 
a familial cancer syndrome. Once a mutation is identified, at-risk family 
members can be offered predictive genetic testing.
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